Cromolyn sodium delays symptoms of ALS in mice, study reveals

Written by Alice Bough (Future Science Group)

A research group from Massachusetts General Hospital (MA, USA) have suggested that the US FDA-approved drug cromolyn sodium could be effective against amyotrophic lateral sclerosis (ALS). The results of their paper, published in Scientific Reports, demonstrated that disease progression was delayed in a mouse model of ALS following injection of the drug.  Recent evidence suggests that ALS may develop as a result of inflammatory processes. To explore this connection, the authors of the paper investigated whether cromolyn sodium could impact disease development. Cromolyn sodium is an anti-inflammatory drug currently approved by the FDA for the treatment of asthma and other inflammatory...

To view this content, please register now for access

It's completely free